CAMBRIDGE, Mass., September 26, 2017 – Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life changing cellular therapies, today announced that it has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.
“We are honored to be selected as a Fierce15 company,” said Torben Straight Nissen, Ph.D., president of Rubius Therapeutics. “Rubius is developing an entirely new class of ready-to-use cell therapeutics to treat cancer, enzyme deficiency disorders and autoimmune diseases – and we are committed to bringing the promise of red cell therapeutics to patients as soon as possible.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fifteenth annual Fierce 15 selection. An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Rubius Therapeutics
Rubius Therapeutics, a 2017 “Fierce 15” award winner, is creating Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications. Leading applications include programs in cancer, rare and autoimmune disease, as well as additional potential in infectious and metabolic diseases. The company was conceived and launched by Flagship VentureLabs®, the institutional innovation foundry where a team of scientific entrepreneurs systematically evolves enterprising ideas into new fields, or previously undiscovered areas of science into real-world inventions and ventures. The company was founded by Flagship Pioneering in 2014 and has been capitalized with $140 million to date. For more information please visit us at www.rubiustx.com.
About Red-Cell Therapeutics™
Red-Cell Therapeutics™ are genetically engineered, enucleated red cells that are being developed to provide allogeneic, off-the-shelf therapies to patients across multiple therapeutic areas. RCT advantages over other therapies include immuno-privileged presentation of proteins within or on the red cell, high target avidity and affinity resulting in highly potent and selective therapies, and long circulation half-life. Rubius RCTs exhibit fundamentally unique biology and have been engineered to replace missing enzymes for patients living with a variety of rare diseases, to kill tumors, and upregulate or downregulate the immune system to treat both cancer and autoimmune disorders.